Intriguingly, the T-αFGL2 treatment increased CXCR3 expression on CD69+CD8+ TM cells in glioma-bearing brains compared with T-Ctr treatment (Fig. 8a). The gene discussed is CXCR3; the disease is central nervous system cancer.